Cooley advised SystImmune on the transaction.SystImmune announced its exclusive license and collaboration agreement with Bristol Myers Squibb (NYSE: BMY) for SystImmune’s BL-B01D1. Under the terms of the…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
